Tags

Type your tag names separated by a space and hit enter

Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Eur Urol. 2007 Jan; 51(1):235-42.EU

Abstract

OBJECTIVES

To compare the efficacy and tolerability of propiverine and oxybutynin in patients with neurogenic detrusor overactivity.

METHODS

Patients were eligible, if at least 18 years of age and suffering from neurogenic detrusor overactivity. Eligibility also required a maximum cystometric capacity less than 300 ml. After a one-week run-in period, propiverine 15 mg t.i.d. or oxybutynin 5mg t.i.d. were administered for 21 days. As primary efficacy outcomes urodynamic parameters were assessed. As tolerability outcome the percentage of patients with newly manifesting anticholinergic adverse events was taken.

RESULTS

131 patients were recruited at 20 study centers. The maximum cystometric capacity (ml) was increased significantly in the propiverine group from 198 (+/-110) to 309 (+/-166), and in the oxybutynin group from 164 (+/-64) to 298 (+/-125). Similarly, maximum detrusor pressure during the filling phase (cm H(2)O) was lowered significantly in the propiverine group from 56.8 (+/-36.2) to 37.8 (+/-31.6), and in the oxybutynin group from 68.6 (+/-34.5) to 43.1 (+/-29.2). No significant differences resulted between treatment groups. Anticholinergic adverse events were reported less frequently in the propiverine compared to the oxybutynin group (63.0% versus 77.8%). Dryness of the mouth, the most frequent adverse event, was reported significantly less (47.1% versus 67.2%; p=0.02) in the propiverine compared to the oxybutynin group.

CONCLUSION

Propiverine and oxybutynin are equally effective in increasing bladder capacity and lowering bladder pressure in patients with neurogenic detrusor overactivity. The trend for better tolerability of propiverine compared to oxybutynin achieved significance for dryness of the mouth.

Authors+Show Affiliations

Department of Urology, Traumatological Hospital, Murnau, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16698176

Citation

Stöhrer, Manfred, et al. "Propiverine Compared to Oxybutynin in Neurogenic Detrusor Overactivity--results of a Randomized, Double-blind, Multicenter Clinical Study." European Urology, vol. 51, no. 1, 2007, pp. 235-42.
Stöhrer M, Mürtz G, Kramer G, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007;51(1):235-42.
Stöhrer, M., Mürtz, G., Kramer, G., Schnabel, F., Arnold, E. P., & Wyndaele, J. J. (2007). Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. European Urology, 51(1), 235-42.
Stöhrer M, et al. Propiverine Compared to Oxybutynin in Neurogenic Detrusor Overactivity--results of a Randomized, Double-blind, Multicenter Clinical Study. Eur Urol. 2007;51(1):235-42. PubMed PMID: 16698176.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. AU - Stöhrer,Manfred, AU - Mürtz,Gerd, AU - Kramer,Guus, AU - Schnabel,Frieder, AU - Arnold,Edwin P, AU - Wyndaele,Jean-Jaques, AU - ,, Y1 - 2006/05/02/ PY - 2005/12/15/received PY - 2006/03/06/accepted PY - 2006/5/16/pubmed PY - 2007/3/21/medline PY - 2006/5/16/entrez SP - 235 EP - 42 JF - European urology JO - Eur Urol VL - 51 IS - 1 N2 - OBJECTIVES: To compare the efficacy and tolerability of propiverine and oxybutynin in patients with neurogenic detrusor overactivity. METHODS: Patients were eligible, if at least 18 years of age and suffering from neurogenic detrusor overactivity. Eligibility also required a maximum cystometric capacity less than 300 ml. After a one-week run-in period, propiverine 15 mg t.i.d. or oxybutynin 5mg t.i.d. were administered for 21 days. As primary efficacy outcomes urodynamic parameters were assessed. As tolerability outcome the percentage of patients with newly manifesting anticholinergic adverse events was taken. RESULTS: 131 patients were recruited at 20 study centers. The maximum cystometric capacity (ml) was increased significantly in the propiverine group from 198 (+/-110) to 309 (+/-166), and in the oxybutynin group from 164 (+/-64) to 298 (+/-125). Similarly, maximum detrusor pressure during the filling phase (cm H(2)O) was lowered significantly in the propiverine group from 56.8 (+/-36.2) to 37.8 (+/-31.6), and in the oxybutynin group from 68.6 (+/-34.5) to 43.1 (+/-29.2). No significant differences resulted between treatment groups. Anticholinergic adverse events were reported less frequently in the propiverine compared to the oxybutynin group (63.0% versus 77.8%). Dryness of the mouth, the most frequent adverse event, was reported significantly less (47.1% versus 67.2%; p=0.02) in the propiverine compared to the oxybutynin group. CONCLUSION: Propiverine and oxybutynin are equally effective in increasing bladder capacity and lowering bladder pressure in patients with neurogenic detrusor overactivity. The trend for better tolerability of propiverine compared to oxybutynin achieved significance for dryness of the mouth. SN - 0302-2838 UR - https://www.unboundmedicine.com/medline/citation/16698176/Propiverine_compared_to_oxybutynin_in_neurogenic_detrusor_overactivity__results_of_a_randomized_double_blind_multicenter_clinical_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(06)00345-9 DB - PRIME DP - Unbound Medicine ER -